<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210223050471N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-02-28</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>The effectiveness of Artemisia absinthium on sexual performance and satisfaction of women</public_title>
      <acronym></acronym>
      <scientific_title>The effectiveness of Artemisia absinthium on sexual performance and satisfaction of women of reproductive age.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-04-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>76</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/54518</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The random sequence of samples is done using random allocation software in two groups A and B Which are intervention and control groups. For Allocation concealment will be using sealed envelopes. A number of envelopes are prepared and each of the random sequences is written on a card and the cards inside the envelope are placed in order and the outer surface of the envelopes is numbered in the same order. Then envelope lids are then glued and placed in the box, respectively. At the beginning of the registration of participants, After giving the necessary explanations to each of the participants and obtaining informed consent, one of the envelopes will be opened in order for the eligible participants to arrive, and the assigned group of the participant will be determined, Blinding description: The drug is placed in two identical boxes and none of the study subjects will be aware of the contents of the boxes except the pharmacist consultant. Depending on the group of participants, gel A or B, previously named by the pharmacist consultant, is given to participants.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Sexual function. Condition 2: Sexual satisfaction.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Wormwood with the scientific name (Artemisia absinthium) belongs to the Asteraceae family and is one of the warm native plants, especially in the eastern and northern regions of Iran, and is known as Kharagoush, Gondvash, Marwa and Wormwood. Phytochemical studies of wormwood include a variety of chemical compounds including carbohydrates, alkaloids, saponins, phytosterols, proteins, amino acids, tannins, phenolic compounds, flavonoids. In this study, a vaginal gel tube of 100 g of 5% wormwood (equivalent to 250 mg of available extract) is used. Wormwood is purchased from the approved centers of the university and under the supervision of the esteemed pharmacist of the project, after grinding it, it is soaked in 70% hydroalcoholic solution for 3 days. After this, the desired hydroalcoholic extract is filtered and after removing the solvent, the final extract is obtained. Then the vaginal gel of this extract is prepared based on carbapol with a concentration of 5%. For standardization, the product in terms of total phenol will be standardized by spectrophotometric method. Then it is coded and given to women blindly and they are asked to use this gel vaginally for 4 weeks and 3 times a week (before going to bed) and in case of intercourse, 30 minutes before intercourse. Intervention 2: Control group: In the present study, placebo means a base gel (carbapol) without wormwood extract, which is prepared under the supervision of a pharmacist. The appearance of this gel is similar to the worm wood  gel. The method of using this gel is similar to the main drug (wormwood gel), 4 weeks and 3 times a week (before going to bed) and in case of intercourse, 30 minutes before sexual intercourse vaginally.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The data will be shared after it becomes unrecognizable

When:
6 months after recording the results

To whom:
All researchers

Conditions:
All women with dysfunction and sexual satisfaction

Where to obtain:
Email niloofarhajatpoor@gmail.com Library of Mashhad School of Nursing to Mashhad, ِDaneshgah Street.

How to obtain:
First, send a requested email and if you do not respond within a week, you can refer to the library of Mashhad School of Nursing.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Raheleh Babazadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nursing and Midwifery, Daneshgah Street</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9137913199</zip>
        <telephone>+98 51 3859 1511</telephone>
        <email>Babazadehr@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Raheleh Babazadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nursing and Midwifery, Daneshgah Street</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9137913199</zip>
        <telephone>+98 51 3859 1511</telephone>
        <email>Babazadehr@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Married women 18-45 years old
Minimum literacy
Having conscious satisfaction
Iranian nationality
Resident of Mashhad
Married and only husband's wife
No history of pelvic surgery
Absence of infertility
Do not use drugs and alcohol in a wife or spouse
Absence of any sexual dysfunction in the spouse
Absence of pregnancy and lactation
Do not take drugs that affect sexual function by the wife or spouse
No recent use of hormonal drugs
Having at least once a week of normal vaginal sex
Absence of abnormal vaginal bleeding
Having a regular menstrual cycle with normal bleeding
No history of chemotherapy and radiotherapy to the pelvis or the whole body
Lack of known medical and psychological illnesses affecting the sexual function of oneself or one's spouse
No depression, anxiety, severe stress
Sexual function score less than 28 and sexual satisfaction score less than 50</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Drug allergy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Wormwood with the scientific name (Artemisia absinthium) belongs to the Asteraceae family and is one of the warm native plants, especially in the eastern and northern regions of Iran, and is known as Kharagoush, Gondvash, Marwa and Wormwood. Phytochemical studies of wormwood include a variety of chemical compounds including carbohydrates, alkaloids, saponins, phytosterols, proteins, amino acids, tannins, phenolic compounds, flavonoids. In this study, a vaginal gel tube of 100 g of 5% wormwood (equivalent to 250 mg of available extract) is used. Wormwood is purchased from the approved centers of the university and under the supervision of the esteemed pharmacist of the project, after grinding it, it is soaked in 70% hydroalcoholic solution for 3 days. After this, the desired hydroalcoholic extract is filtered and after removing the solvent, the final extract is obtained. Then the vaginal gel of this extract is prepared based on carbapol with a concentration of 5%. For standardization, the product in terms of total phenol will be standardized by spectrophotometric method. Then it is coded and given to women blindly and they are asked to use this gel vaginally for 4 weeks and 3 times a week (before going to bed) and in case of intercourse, 30 minutes before intercourse.</i_keyword>
      <i_keyword>Control group: In the present study, placebo means a base gel (carbapol) without wormwood extract, which is prepared under the supervision of a pharmacist. The appearance of this gel is similar to the worm wood  gel. The method of using this gel is similar to the main drug (wormwood gel), 4 weeks and 3 times a week (before going to bed) and in case of intercourse, 30 minutes before sexual intercourse vaginally.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Sexual function score. Timepoint: At the beginning of the study and 4 weeks after using the gel. Method of measurement: The Female Sexual Function Index Questionnaire.</prim_outcome>
      <prim_outcome>Sexual satisfaction score. Timepoint: At the beginning of the study and 4 weeks after using the gel. Method of measurement: Larson Sexual Satisfaction Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-01-26</approval_date>
        <contact_name>Ethics Committee of Mashhad University of Medical Sciences</contact_name>
        <contact_address>Mashhad University of Medical Sciences, Vice Chancellor for Research, Qureshi building, Daneshgah Street Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
